OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Novel therapeutic approaches in chronic myeloid leukemia
Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
Leukemia Research (2020) Vol. 91, pp. 106337-106337
Closed Access | Times Cited: 40
Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
Leukemia Research (2020) Vol. 91, pp. 106337-106337
Closed Access | Times Cited: 40
Showing 26-50 of 40 citing articles:
Developing therapeutic approaches for chronic myeloid leukemia: a review
Veerandra Kumar, Jyotirmayee, Malkhey Verma
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 5, pp. 1013-1029
Closed Access | Times Cited: 4
Veerandra Kumar, Jyotirmayee, Malkhey Verma
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 5, pp. 1013-1029
Closed Access | Times Cited: 4
Artemisia vulgaris inhibits BCR/ABL and promotes apoptosis in chronic myeloid leukemia cells
Hoang Chi, Bùi Thị Kim Lý
Biomedical Reports (2022) Vol. 17, Iss. 6
Open Access | Times Cited: 3
Hoang Chi, Bùi Thị Kim Lý
Biomedical Reports (2022) Vol. 17, Iss. 6
Open Access | Times Cited: 3
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
Reyhan Yılmaz, Ahmet Emre Eşkazan
Future Oncology (2023) Vol. 19, Iss. 8, pp. 545-547
Closed Access | Times Cited: 1
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia
Andrew Wu, Liu Xiao-hu, Clark Fruhstorfer, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3307-3307
Open Access
Andrew Wu, Liu Xiao-hu, Clark Fruhstorfer, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3307-3307
Open Access
Chunmei Guo, Xinxin Lv, Qiuling Zhang, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 9
Open Access
Introduction to cancer cell biology
Mohammad Arshad Javed Shaikh, Salman Hussain, Ritu Gilhotra, et al.
Elsevier eBooks (2021), pp. 1-7
Closed Access | Times Cited: 2
Mohammad Arshad Javed Shaikh, Salman Hussain, Ritu Gilhotra, et al.
Elsevier eBooks (2021), pp. 1-7
Closed Access | Times Cited: 2
The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants
Ye Wu, Xia Wu, Xiao‐Jia Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 1
Ye Wu, Xia Wu, Xiao‐Jia Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 1
Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients
Mohamed A. Ismail, Claudio Sorio, Nader Al‐Dewik
Cancer Control (2022) Vol. 29
Open Access | Times Cited: 1
Mohamed A. Ismail, Claudio Sorio, Nader Al‐Dewik
Cancer Control (2022) Vol. 29
Open Access | Times Cited: 1
Integrated Chemical Characterization, Network Pharmacology and Transcriptomics to Explore the Mechanism of Sesquiterpenoids Isolated from Gynura divaricata (L.) DC. against Chronic Myelogenous Leukemia
Xinyuan Ye, Long Wang, Xin Yang, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1435-1435
Open Access | Times Cited: 1
Xinyuan Ye, Long Wang, Xin Yang, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1435-1435
Open Access | Times Cited: 1
Inhibition of Casein Kinase 2 induces cell death in chronic myelogenous leukemia cells resistant to tyrosine kinase inhibitors
Ondřej Mitrovský, Denisa Myslivcová, Tereza Macháčková-Lopotová, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 1
Ondřej Mitrovský, Denisa Myslivcová, Tereza Macháčková-Lopotová, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 1
Inhibitory Effect of Ouabain on Resistance to Imatinib in Chronic Myeloid Leukemia K562/G01 Cells
Sun Chang, Jian Liu, S. Zhai, et al.
Indian Journal of Pharmaceutical Sciences (2023) Vol. 85, Iss. 3
Open Access
Sun Chang, Jian Liu, S. Zhai, et al.
Indian Journal of Pharmaceutical Sciences (2023) Vol. 85, Iss. 3
Open Access
In the Pipeline: Emerging Therapy for CML
Harinder Gill, Emily Lee, Pinky Mo
(2023), pp. 663-684
Closed Access
Harinder Gill, Emily Lee, Pinky Mo
(2023), pp. 663-684
Closed Access
CRKL but not CRKII Inhibits Erythropoiesis and Megakaryopoiesis of CML via Inactivating Raf/MEK/ERK/Elk-1 Pathway
Chunmei Guo, Qiuling Zhang, Jinsong Yan, et al.
Research Square (Research Square) (2020)
Open Access
Chunmei Guo, Qiuling Zhang, Jinsong Yan, et al.
Research Square (Research Square) (2020)
Open Access
Agaricus blazei extract FA2bβ enhances the sensitivity of K562/ADR cells through the PI3K/Akt/mTOR signalling pathway
dongping wang, Wanwen Ge, Yanqing Sun
Research Square (Research Square) (2022)
Open Access
dongping wang, Wanwen Ge, Yanqing Sun
Research Square (Research Square) (2022)
Open Access
Tyrosine kinase inhibitor resistance: a case report on chronic myeloid leukemia and Gilbert’s syndrome
Maura Lima Pereira Bueno, Fernanda Marconi Roversi
AME Case Reports (2021) Vol. 5, pp. 1-1
Open Access
Maura Lima Pereira Bueno, Fernanda Marconi Roversi
AME Case Reports (2021) Vol. 5, pp. 1-1
Open Access
